These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 5286991)

  • 1. Evaluation of a combination of mitomycin C (NSC-26980), phenylalanine mustard (NSC-14210), and vincristine (NSC-67574) in the treatment of osteogenic sarcoma.
    Jaffe N; Traggis D; Enriquez C
    Cancer Chemother Rep; 1971 Apr; 55(2):189-91. PubMed ID: 5286991
    [No Abstract]   [Full Text] [Related]  

  • 2. L-phenylalanine mustard (NSC-8806) administration in osteogenic sarcoma: an evaluation of dosage schedules.
    Sutow WW; Sullivan MP; Wilbur JR; Vietti TJ; Kaizer H; Nagamoto A
    Cancer Chemother Rep; 1971 Apr; 55(2):151-7. PubMed ID: 5286989
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma.
    Sutow WW; Vietti TJ; Fernbach DJ; Lane DM; Donaldson MH; Lonsdale D
    Cancer Chemother Rep; 1971 Feb; 55(1):67-78. PubMed ID: 5287340
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of mitomycin C (NSC-26980) in the treatment of metastatic osteogenic sarcoma.
    Evans AE; Heyn RM; Nesbit ME; Hartmann JR
    Cancer Chemother Rep; 1969 Oct; 53(5):297-8. PubMed ID: 5270582
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.
    Sutow WW; Wilbur JR; Vietti TJ; Vuthibhagdee P; Fujimoto T; Watanabe A
    Cancer Chemother Rep; 1971 Jun; 55(3):285-9. PubMed ID: 4107239
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.
    Sutow WW; Sullivan MP; Fernbach DJ; Cangir A; George SL
    Cancer; 1975 Nov; 36(5):1598-602. PubMed ID: 1059501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteogenic sarcoma of the fourth thoracic vertebra. Long-term survival by chemotherapy only.
    Ogihara Y; Sekiguchi K; Tsuruta T
    Cancer; 1984 Jun; 53(12):2615-8. PubMed ID: 6586274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for osteogenic sarcoma.
    Etcubanas E; Wilbur JR
    Cancer Treat Rep; 1978 Feb; 62(2):283-7. PubMed ID: 346218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy in the treatment of osteogenic sarcoma of the maxilla (case report).
    Yokobayashi T; Nakajima T
    J Maxillofac Surg; 1978 Nov; 6(4):273-6. PubMed ID: 83344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in osteogenic sarcoma.
    Tichler TE; Am YB; Brenner HJ
    Prog Clin Biol Res; 1982; 99():49-75. PubMed ID: 6983080
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
    Nichols M; Bergevin PR; Vyas AC; Hamilin R
    Cancer Treat Rep; 1976 Mar; 60(3):293-4. PubMed ID: 1260786
    [No Abstract]   [Full Text] [Related]  

  • 13. Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-26271), and vincristine (NSC-67574).
    Gasparini M; Bellani FF; Musumeci R; Bonadonna G
    Cancer Chemother Rep; 1974; 58(3):365-70. PubMed ID: 4601666
    [No Abstract]   [Full Text] [Related]  

  • 14. Multidrug chemotherapy in pulmonary treatment of osteosarcoma.
    Sutow WW; Gehan EA; Vietti TJ; Frias AE; Dyment PG
    J Bone Joint Surg Am; 1976 Jul; 58(5):629-33. PubMed ID: 1084348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma.
    Nelson JA; Hokanson JA; Jenkins VK
    Cancer Chemother Pharmacol; 1982; 9(3):148-55. PubMed ID: 6961973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment results in osteogenic sarcoma in children and adolescents with the use of karminomycin].
    Bizer VA; Timukhina VN
    Antibiotiki; 1984 Jan; 29(1):56-9. PubMed ID: 6582798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.
    Houghton JA; Cook RL; Lutz PJ; Houghton PJ
    Eur J Cancer Clin Oncol; 1984 Jul; 20(7):955-60. PubMed ID: 6430707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].
    Kaneko M; Kaneko S; Ohkawa H
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1155-61. PubMed ID: 1905121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of 5-FU, vincristine, and mitomycin (FOMi) in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group Study.
    Miller TP; Livingston RB
    Cancer Treat Rep; 1985 Nov; 69(11):1313-4. PubMed ID: 3004726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone.
    Starling KA; Sutow WW; Donaldson MH; Land VJ; Lane DM
    Cancer Chemother Rep; 1974; 58(5 Pt 1):683-8. PubMed ID: 4426047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.